Core Viewpoint - The market anticipates Green Plains Renewable Energy (GPRE) to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - GPRE is expected to post a quarterly loss of $0.28 per share, reflecting a year-over-year change of +26.3%, while revenues are projected to be $592.3 million, down 4.3% from the previous year [3]. - The consensus EPS estimate has been revised 44.44% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent analyst revisions may provide more accurate predictions [8]. - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, with a historical success rate of nearly 70% for such combinations [10]. Current Analyst Sentiment - For GPRE, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.09%, indicating a bearish outlook from analysts [12]. - The stock currently holds a Zacks Rank of 3, complicating predictions for an earnings beat [12]. Historical Performance - In the last reported quarter, GPRE was expected to post a loss of $0.51 per share but actually reported a loss of -$0.88, resulting in a surprise of -72.55% [13]. - Over the past four quarters, GPRE has only beaten consensus EPS estimates once [14]. Conclusion - GPRE does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding the stock ahead of its earnings release [17].

Henry Schein (HSIC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than expectati ...

Halozyme Therapeutics (HALO) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than ...

Core Viewpoint - Karyopharm Therapeutics (KPTI) is expected to report a year-over-year decline in earnings and revenues for the quarter ended June 2025, with the consensus outlook indicating a loss of $3.80 per share and revenues of $40.08 million, reflecting a 26.7% and 6.3% decrease respectively [1][3]. Earnings Expectations - The upcoming earnings report could lead to a stock price increase if the actual results exceed expectations, while a miss could result in a decline [2]. - The consensus EPS estimate has been revised 2.21% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that Karyopharm has a positive Earnings ESP of +0.92%, indicating a likelihood of beating the consensus EPS estimate [12]. - The stock currently holds a Zacks Rank of 3, which supports the potential for an earnings beat [12]. Historical Performance - Karyopharm has a history of exceeding consensus EPS estimates, having beaten expectations in the last four quarters [14]. - In the last reported quarter, the company was expected to post a loss of $4.21 per share but actually reported a loss of -$2.77, resulting in a positive surprise of +34.20% [13]. Industry Context - In the Zacks Medical - Drugs industry, Ardelyx (ARDX) is expected to report a loss of $0.13 per share, indicating a significant year-over-year decline of 85.7%, with revenues projected at $84.64 million, up 15.6% from the previous year [18]. - Ardelyx's consensus EPS estimate has been revised 6.3% lower, resulting in a negative Earnings ESP of -6.18%, combined with a Zacks Rank of 4, making it difficult to predict an earnings beat [19].

Core Viewpoint - Lithia Motors reported quarterly earnings of $10.24 per share, exceeding the Zacks Consensus Estimate of $9.78 per share, and showing an increase from $7.87 per share a year ago, indicating a positive earnings surprise of +4.70% [1][2] Financial Performance - The company achieved revenues of $9.58 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.52%, and up from $9.23 billion in the same quarter last year [2] - Over the last four quarters, Lithia Motors has exceeded consensus EPS estimates three times and topped revenue estimates twice [2] Stock Performance - Lithia Motors shares have declined approximately 14.1% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Lithia Motors is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $8.88 on revenues of $9.83 billion, while for the current fiscal year, the estimate is $35.14 on revenues of $38.55 billion [7] - The outlook for the automotive retail and wholesale industry, where Lithia Motors operates, is currently in the bottom 37% of Zacks industries, which may impact stock performance [8]

Core Viewpoint - Cincinnati Financial (CINF) reported quarterly earnings of $1.97 per share, exceeding the Zacks Consensus Estimate of $1.39 per share, and showing an increase from $1.29 per share a year ago, representing an earnings surprise of +41.73% [1][2] Financial Performance - The company posted revenues of $2.78 billion for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.14%, compared to $2.41 billion in the same quarter last year [2] - Over the last four quarters, Cincinnati Financial has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Cincinnati Financial shares have increased by approximately 4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.62 on revenues of $2.84 billion, and for the current fiscal year, it is $5.28 on revenues of $11.14 billion [7] - The outlook for the insurance industry, particularly the Property and Casualty sector, is currently in the top 35% of Zacks industries, suggesting a favorable environment for stock performance [8]

Core Insights - V.F. Corporation (VFC) is expected to report a year-over-year decline in both revenue and earnings for the first quarter of fiscal 2026, with revenues estimated at $1.7 billion, reflecting an 11.2% decrease from the previous year [1][9] Revenue Performance - The consensus estimate for VFC's loss is set at 34 cents per share, slightly wider than the 33 cents reported in the same quarter last year [2] - Management anticipates a revenue decline of 3-5% on a constant currency basis, primarily due to brand-specific challenges and reduced consumer traffic [3] - Vans brand performance is expected to mirror a 20% decline seen in the previous quarter, significantly impacting overall revenue [4] Operational Challenges - The fiscal first quarter is typically the smallest for VFC and is heavily influenced by Vans' performance, with ongoing strategic resets and store closures affecting results [3][4] - Foreign exchange fluctuations are also expected to negatively impact revenue, adding further pressure [5] Margin and Cost Structure - Despite revenue challenges, gross margin is projected to remain strong due to lower input costs, fewer promotions, and an improved inventory mix, which previously led to a 560 basis-point improvement in gross margin [6][9] - Operating loss is expected to be between $110 million and $125 million for the first quarter, with SG&A expenses forecasted to be flat or slightly down year-over-year due to cost-saving measures [6] Stock Valuation - VFC's stock is currently trading at a forward price-to-earnings ratio of 13.87, which is higher than the industry average of 11.49 [10] - Over the past three months, VFC's shares have increased by 8.2%, outperforming the industry growth of 1.1% [11]

Core Viewpoint - AbbVie is expected to report second-quarter 2025 earnings on July 31, with sales estimated at $15.07 billion and earnings per share (EPS) at $2.89, although earnings estimates have declined recently [1][4][5] Financial Performance - AbbVie has consistently exceeded earnings expectations in the past four quarters, with an average earnings surprise of 2.93% [2][3] - The company anticipates adjusted earnings between $2.84 and $2.88 per share for Q2 2025, with net revenues around $15.0 billion [5] Product Performance - Growth is expected to be driven by newer immunology drugs, Skyrizi and Rinvoq, with sales estimates of $4.12 billion and $1.98 billion respectively [6] - Humira, which lost patent protection in January 2023, is projected to generate $1.41 billion in sales, reflecting ongoing sales erosion [7] - Sales for Imbruvica are expected to decline due to competition, with estimates at $704 million [8] - Venclexta sales are likely to rise, estimated at $668 million, driven by strong demand [9] - Neuroscience product sales are projected at $2.47 billion, supported by strong growth in drugs like Botox and Vraylar [10][11] Market Position and Valuation - AbbVie shares have outperformed the industry this year, trading at a price/earnings ratio of 14.44, slightly below the industry average of 15.34 [13][16] - Despite challenges from Humira biosimilars, AbbVie expects robust revenue growth in 2025, with a projected high single-digit revenue CAGR through 2029 [18] Strategic Outlook - AbbVie is investing in its future pipeline through collaborations, including a recent licensing deal for an investigational antibody targeting oncology and autoimmune diseases [20] - The company’s diverse portfolio, including drugs like Venclexta, Vraylar, and others, is expected to offset losses from declining sales in certain areas [19]

Key Takeaways Vale S.A. (VALE) is expected to report a decline in its bottom and top lines when it reports second-quarter 2025 results on July 31, after market close. The Zacks Consensus Estimate for Vale's sales is pegged at $8.66 billion, indicating a 12.7% decrease from the year-ago quarter's figure. The consensus mark for earnings has moved down 25% over the past 60 days to 33 cents per share. The figure indicates a 23% year-over-year decline. | | Q1 | Q2 | F1 | F2 | | --- | --- | --- | --- | --- | | Cu ...

Core Viewpoint - Navient Corporation (NAVI) is expected to report a rise in quarterly revenues but a decline in earnings year-over-year for Q2 2025 [1][8] Revenue Expectations - The consensus estimate for revenues is $142.8 million, indicating a 5% increase compared to the previous year [2] - Consumer loan demand remained stable due to a strong labor market, which is expected to positively impact the Consumer Lending segment [3] - However, elevated prepayment due to student loan forgiveness and subdued origination volume are likely to limit revenue growth in the Federal Education Loans segment [3] Earnings Expectations - The Zacks Consensus Estimate for earnings is 29 cents per share, reflecting a 39.6% decline from the year-ago figure [2] - NAVI's earnings surprise history shows an average surprise of 27.10%, with earnings exceeding estimates in four of the last five quarters [2] Net Interest Income (NII) - The consensus estimate for Core NII is $142.9 million, indicating a sequential decline of 0.8% [4] - NII for Federal Education loans is estimated at $48.6 million, suggesting a slight rise, while consumer lending NII is expected to decline by 1.4% to $111.5 million [4] Non-Interest Income - The consensus estimate for servicing revenues is $10 million, indicating a 23.3% fall from the prior quarter [5] - Total non-interest income is estimated at $25.1 million, reflecting a 50.7% sequential decline [5] Expense Management - Cost-control measures are anticipated to enhance operating efficiency and lower expenses in Q2 2025 [6] - Strategic actions taken last year are expected to contribute to a further decline in operating expenses [6] Earnings ESP and Zacks Rank - NAVI has an Earnings ESP of -7.66%, indicating a lower likelihood of an earnings beat [7] - The company currently holds a Zacks Rank of 3 (Hold) [9]